bibp omicron inactivated covid-19 vaccine (vero cell)
Vaccineexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 27, 2022 (NCT05382871)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05593042 | Phase 2 | Oct 31, 2022 | China National Pharmaceutical Group, Pontificia Universidad Catolica de Chile |
| NCT05382871 | Phase 3 | May 27, 2022 | Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, The University of Hong Kong, Wuhan Institute of Biological Products Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Tiantan Bio Co., Ltd | For profit | 1 | 0 | 1 | 2022 |
| China National Biotec Group Co., Ltd | For profit | 1 | 1 | 1 | 2022 |
| China National Pharmaceutical Group | For profit | 1 | 0 | 1 | 2022 |
| Pontificia Universidad Catolica de Chile | Academic/Hospital | 1 | 1 | 1 | 2022 |
| The University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Wuhan Institute of Biological Products Co., Ltd | Government | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1